MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, SLNO had -$17,822K decrease in cash & cash equivalents over the period. $46,725K in free cash flow.

Cash Flow Overview

Change in Cash
-$17,822K
Free Cash flow
$46,725K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Proceeds from the sale of common...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Payment for repurchase of common...
    • Accounts receivable
    • Others

Cash Flow
2025-12-31
Net income (loss)
20,890
Depreciation and amortization
2,017
Accretion of premium/discount on marketable securities
3,517
Non-cash lease expense
607
Amortization of debt issuance costs
35
Stock-based compensation expense
45,846
Change in fair value of stock warrants
0
Change in fair value of contingent consideration
5,536
Other non-cash reconciling items
-17
Accounts receivable
28,208
Inventory
14,031
Prepaid expenses, other current assets and other assets
4,738
Accounts payable
3,612
Accrued compensation
4,901
Operating lease liabilities
-308
Other liabilities
14,139
Net cash provided by (used in) operating activities
46,798
Purchases of property and equipment
73
Purchases of marketable securities
455,776
Maturities of marketable securities
254,068
Net cash used in investing activities
-201,781
Proceeds from issuance of debt, net of issuance costs
0
Payment of debt issuance costs
62
Proceeds from the sale of common stock, net of issuance costs
215,721
Proceeds from the sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs
0
Payment for repurchase of common stock
100,146
Proceeds from exercise of common stock and pre-funded stock warrants
5,187
Proceeds from exercise of stock options
17,202
Tax withholding payments for net share-settled equity awards
741
Net cash provided by financing activities
137,161
Net increase (decrease) in cash and cash equivalents
-17,822
Cash and cash equivalents, beginning of period
87,928
Cash and cash equivalents, end of period
70,106
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from the sale ofcommon stock, net of...$215,721K Stock-based compensationexpense$45,846K Net income (loss)$20,890K Proceeds from exercise ofstock options$17,202K Proceeds from exercise ofcommon stock and...$5,187K Other liabilities$14,139K Change in fair value ofcontingent consideration$5,536K Accrued compensation$4,901K Accounts payable$3,612K Depreciation andamortization$2,017K Non-cash lease expense$607K Amortization of debt issuancecosts$35K Other non-cashreconciling items-$17K Net cash provided byfinancing activities$137,161K Net cash provided by(used in) operating...$46,798K Canceled cashflow$100,949K Canceled cashflow$50,802K Net increase(decrease) in cash and cash...-$17,822K Canceled cashflow$183,959K Maturities of marketablesecurities$254,068K Payment for repurchaseof common stock$100,146K Tax withholdingpayments for net...$741K Payment of debt issuancecosts$62K Accounts receivable$28,208K Inventory$14,031K Prepaid expenses, othercurrent assets and other...$4,738K Accretion ofpremium/discount on marketable...$3,517K Operating leaseliabilities-$308K Net cash used ininvesting activities-$201,781K Canceled cashflow$254,068K Purchases of marketablesecurities$455,776K Purchases of property andequipment$73K

SOLENO THERAPEUTICS INC (SLNO)

SOLENO THERAPEUTICS INC (SLNO)